(Q43200906)

English

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

scientific article published in March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1 reference

based on heuristic

inferred from title

adult acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Shigeki Ohtake

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Shuichi Miyawaki

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Hitoshi Kiyoi

3

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Yasushi Miyazaki

4

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Hirokazu Okumura

5

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Shin Matsuda

6

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Tadashi Nagai

7

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Yuji Kishimoto

8

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Masaya Okada

9

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Masatomo Takahashi

10

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Hiroshi Handa

11

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Jin Takeuchi

12

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Shinichi Kageyama

13

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Norio Asou

14

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Fumiharu Yagasaki

15

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Yasuhiro Maeda

16

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Kazunori Ohnishi

17

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Tomoki Naoe

18

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Ryuzo Ohno

19

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

publication date

1 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

276-283

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

https://scigraph.springernature.com/pub.10.1007/s12185-009-0480-5

0 references

Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How high can we increase complete remission rate in adult acute myeloid leukemia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of daunorubicin in the induction therapy for adult acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20054669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-009-0480-5

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43200906&oldid=1983653313"